KEBOMED AS
Score · fiscal year 2025
65of 100
How to read this: the company is ahead of 81 % of medium-sized companies in the same sector in 2025. What does this mean?
Rank: 7,696 of 38,671 · Handel
Profile
Lion · Leader
High profitability, high solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 55 and solidity 68 out of 100 among medium-sized companies in the same sector in 2025. Methodology
Against the sector
KEBOMED AS is 16 points above the median for medium-sized companies in the same sector in 2025.
Median score 49 among 2,198 companies.
Against medium-sized companies in the same sector in 2025: operating margin 4.4% (median 3.2%) and equity ratio 46.4% (median 32.6%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 157 MNOK | 173 MNOK |
| Operating margin | 4.4% | 3.2% |
| Profit margin | 4.8% | 3.2% |
| Return on assets | 10.9% | 11.6% |
| Equity ratio | 46.4% | 32.6% |
| Debt-to-equity | 1.16 | 2.03 |
| Current ratio | 1.86 | 1.38 |
| Revenue growth | 27.0% | 6.8% |
| Revenue per employee | 5.80 MNOK | 6.45 MNOK |
The median and “ahead of” refer to medium-sized companies in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 65, KEBOMED AS does better than 81% of medium-sized companies in the same sector (2,203 companies) in 2025.
Score 2023–2025
- KEBOMED AS
- Median: medium-sized companies in the same sector
KEBOMED AS has a score of 65 for 2025, rank 7,696 of 38,671 in the sector.
Strongest: Growth: percentile 84 against peers, revenue growth 27.0% against a median of 6.8%. Liquidity: percentile 72 against peers, current ratio 1.86 against a median of 1.38.
No area is clearly below its peers.
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
KEBOMED AS had an operating margin of 4.4% and an equity ratio of 46.4% in 2025, and ranks 7,696 of 38,671 in Handel.
From 2024 to 2025: revenue grew by 27% and the operating margin fell from 8.1% to 4.4%.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 35 MNOK and 68 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 57 MNOK |
| EV/EBIT | 8.0 | 68 MNOK |
| P/B | 1.0 | 35 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
No rules were triggered for this year.
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2017, the sector's weakest year, for this company.
The sector's weakest year was 2017, with a median operating margin of −65.6%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 55 | weight 30% |
|---|---|---|
| Solidity | 68 | weight 25% |
| Liquidity | 72 | weight 15% |
| Growth | 84 | weight 15% |
| Consistency | 55 | weight 15% |
Durability: 70 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is KEBOMED AS?
The operating margin was 4.4% in 2025, against a median of 3.2% among medium-sized companies in the same sector. Return on assets was 10.9%.
How solid is KEBOMED AS?
The equity ratio was 46.4% in 2025 (median 32.6%). Debt-to-equity was 1.16 (median 2.03).
What is the liquidity of KEBOMED AS like?
The current ratio was 1.86 in 2025 (median 1.38).
How does KEBOMED AS compare in Handel?
KEBOMED AS ranks 7,696 of 38,671 in Handel for 2025. Among companies of the same size (medium-sized companies) it ranks 411 of 2,203. Revenue changed by 27.0% from the year before.
Group accounts
The company is registered as part of a group, but we have no group accounts for it. Group accounts are filed by the parent company, and open data does not say which company that is.
Read the figures with care: a company in a group can look strong because of group contributions, or weak because dividends go up to the parent. The figures are indications, not the full picture.
We do not show the group structure, because open data does not say who owns whom.
Public contracts
- Contracts awarded since 2024
- 13
- Total awarded value since 2024
- value not stated
- 11 contracts without a stated value are not in the total.
- Framework agreements
- 2
- Left out of the total: the value is a ceiling, not actual spend.
Based on notices in Doffin. Does not show call-offs under framework agreements or purchases below the publication threshold. Values are as stated by the buyer.
Source: Doffin (DFØ), fetched 28 October 2026. Winners are matched on organisation number.
Contains data under the Norwegian licence for public data (NLOD 2.0) made available by Doffin/the Norwegian Agency for Public and Financial Management (DFØ). NLOD 2.0
From the Central Coordinating Register
- Org. no.
- 941668844
- Legal form
- AS · part of a group
- Sector
- Handel (46.460)
- Size tier
- medium
- Employees
- 27 registered 10 January 2026
- Founded
- 30 October 1986 39 years in operation
- Share capital
- 5.00 MNOK
- Business address
- Midtunhaugen 17, 5224 NESTTUN (BERGEN)
- Municipality
- Bergen rank 9 of 11 in KOSTRA group 12
- Latest accounts filed
- 2025
- Website
- www.kebomed.no
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Bjarte Ivan Olsen
- Chair of the board
- Lars Løgstrup Poulsen
- Board member
- Henrik Schjødt
- Auditor
- FORVIS MAZARS AS
Source: Central Coordinating Register, fetched 25 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 28 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 70 | 73 | 65 | |
| Rank | 6,127 | 3,466 | 7,696 | |
| Operating margin | 9.3% | 8.1% | 4.4% | |
| Return on assets | 16.8% | 16.1% | 10.9% | |
| Equity ratio | 44.1% | 49.1% | 46.4% | |
| Current ratio | 1.79 | 1.96 | 1.86 | |
| Revenue growth | – | 16.2% | 27.0% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 106.2 MNOK | 123.4 MNOK | 156.7 MNOK |
| Operating profit | 9.9 MNOK | 9.9 MNOK | 6.9 MNOK |
| Profit before tax | 8.3 MNOK | 10.8 MNOK | 7.5 MNOK |
| Net profit | 6.7 MNOK | 8.5 MNOK | 5.7 MNOK |
| Financial expenses | 1.6 MNOK | 0.5 MNOK | 0.6 MNOK |
| Total assets | 59.2 MNOK | 70.5 MNOK | 74.7 MNOK |
| Current assets | 59.2 MNOK | 70.5 MNOK | 74.6 MNOK |
| Equity | 26.1 MNOK | 34.6 MNOK | 34.6 MNOK |
| Retained earnings | 18.9 MNOK | 27.4 MNOK | 27.4 MNOK |
| Total liabilities | 33.1 MNOK | 35.9 MNOK | 40.1 MNOK |
| Current liabilities | 33.1 MNOK | 35.9 MNOK | 40.1 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 28 October 2026, accounts id 6342049.
Further
Similar companies
- CF MASKIN AS index 65, rank 7,639 · compare
- NFT HOLDCO AS index 65, rank 7,662 · compare
- TEKNO MASKIN AS index 65, rank 7,703 · compare
- SUNKOST LOGISTIKK AS index 65, rank 7,708 · compare
- SNA EUROPE (NORWAY) AS index 65, rank 7,710 · compare